# Seraxis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seraxis

- Industry: Biotechnology
- Headquarters: Germantown, US
- Website: www.seraxis.com
- Total disclosed funding: $40M
- Latest round: Series C (Feb 9, 2021)
- Investors on record: 8

## About

Founded in 2013 and based in Germantown, Maryland, Seraxis Inc. operates as a biotechnology company that focuses on cell therapy treatment for diabetes. Mr. William L. Rust is the CEO and co-founder of the company and Miss Carole Welsch is the co-founder and chief business officer. In March 2013, the company raised an undisclosed amount in series A funding from new investors ASAP Ventures, GRI Fund, L.P. and East West Capital Partners.

Seraxis team of scientists developed novel cell and encapsulation technologies. The company provides insulin-dependent diabetes. The company develops SR1423 cells, lab-grown islets for transplant and SeraGraft © device. The company has also developed SeraGraft, an implant device and method that enables survival and function of the cell replacement therapy in the absence of immune suppression.

The company will focus on completing the preclinical testing of SR-01, Seraxis’ lead cell therapy treatment for insulin-dependent diabetes and initiate first-in-human clinical trials.

## Funding rounds

- Series C, Feb 9, 2021, $40M — Frazier Healthcare Partners, Polaris Partners, Eli Lilly & Company, JDRF T1D Fund, Viva Ventures Biotech
- Series A, Mar 1, 2013 — East West Capital Partners, ASAP Ventures, GRI Fund, L.P.

## Investors

- East West Capital Partners (https://capitalatlas.ai/funds/east-west-capital-partners) — Series A
- ASAP Ventures (https://capitalatlas.ai/funds/asap-ventures) — Series A
- GRI Fund, L.P. — Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series C
- Eli Lilly & Company — Series C
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series C
- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series C